A5000691299- Cancer-related molecular mechanisms research
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- Pancreatic and Hepatic Oncology Research
- RNA Research and Splicing
- Nanoparticle-Based Drug Delivery
- Radiopharmaceutical Chemistry and Applications
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Neuroendocrine Tumor Research Advances
- Lung Cancer Treatments and Mutations
- Mycobacterium research and diagnosis
- MicroRNA in disease regulation
- Melanoma and MAPK Pathways
- Microtubule and mitosis dynamics
- Pancreatic function and diabetes
- Endoplasmic Reticulum Stress and Disease
- Neuroblastoma Research and Treatments
- Lung Cancer Diagnosis and Treatment
- Fibroblast Growth Factor Research
- RNA Interference and Gene Delivery
- PI3K/AKT/mTOR signaling in cancer
- Kruppel-like factors research
- Cancer-related Molecular Pathways
University Hospital of Bern
2007-2024
University of Bern
2007-2024
The University of Sydney
2017
Northern Sydney Local Health District
2016
Baylor College of Medicine
2010
Purpose The transcription factor CCAAT/enhancer binding protein-α (CEBPA) is crucial for normal myeloid differentiation. Mutations in the CEBPA gene are found subsets of patients with acute leukemia (AML). Recently, three families were reported whom several family members had germline mutations and subsequently developed AML. Whereas familial AML considered a rare event, frequency not known. Patients Methods In this study, we screened 187 consecutive at diagnosis. We detected 18 (9.6%)...
Non-small cell lung cancer (NSCLC) is characterised by its aggressiveness and poor prognosis. Early detection accurate prediction of therapeutic responses remain critical for improving patient outcomes. In the present study, we investigated potential circulating microRNA (miRNA) as non-invasive biomarkers in patients with NSCLC.
Long noncoding RNAs (lncRNAs) are widely dysregulated in cancer, yet their functional roles cancer hallmarks remain unclear. We employ pooled CRISPR deletion to perturb 831 lncRNAs detected KRAS-mutant non-small cell lung (NSCLC) and measure contribution proliferation, chemoresistance, migration across two backgrounds. Integrative analysis of these data outperforms conventional "dropout" screens identifying genes while prioritizing disease-relevant with pleiotropic background-independent...
Background TLD-1 is a novel liposomal doxorubicin that compared favorably to conventional formulations in preclinical models. This phase I first-in-human study aimed define the maximum tolerated dose (MTD), recommended 2 (RP2D), safety and preliminary activity of patients with advanced solid tumors. Patients methods We recruited tumors who failed standard therapy received up 3 prior lines palliative systemic chemotherapy. was administered intravenously every weeks 9 cycles (6 for...
9505 Background: Immune checkpoint inhibitors (ICI) are front-line standard-of-care treatment (tx) for advanced (unresectable or metastatic) melanoma. Despite recent advances in tx, a majority of patients (pts) do not achieve long-term benefit. Lifileucel, one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, potentially induces durable responses pts with melanoma previously treated ICI. This study evaluates lifileucel combined anti-PD-1 therapy Methods: IOV-COM-202...
Despite significant advancements in our understanding of cancer development, the molecular mechanisms that underlie formation liver remain largely unknown. C/EBPalpha is a transcription factor regulates quiescence. Phosphorylation at serine 193 (S193-ph) upregulated older mice and thought to contribute age-associated dysfunction. Because development tumors associated with increasing age, we investigated role S193-ph using knockin expressing phospho-mimetic aspartic acid residue place...
Abstract Long non-coding RNAs (lncRNAs) play key roles in cancer and are at the vanguard of precision therapeutic development. These efforts depend on large high-confidence collections lncRNAs. Here, we present Cancer LncRNA Census 2 (CLC2). With 492 lncRNAs, CLC2 is 4-fold greater size than its predecessor, without compromising strict criteria confident functional/genetic inclusion GENCODE annotation scheme. This increase was enabled by leveraging high-throughput transposon insertional...
Highly multiplexed, antibody-based protein imaging of tissue has yielded many insights but does not yet allow the routine analysis more than 50 markers simultaneously. By leveraging ability Matrix-Assisted Laser Desorption/Ionization (MALDI) to resolve hundreds m/z peaks without spectral overlap, MALDI-IHC with photocleavable mass-tag (PCMT)-labelled antibodies offers possibility dramatically increase number that can be imaged. Here, we demonstrate 100+ plex and describe our development...
<h3>Background</h3> A majority of patients with advanced NSCLC develop disease progression first-line immune-checkpoint inhibitors (ICI) ± chemotherapy. In the setting ICI resistance, effective strategies to provide deep and durable responses are urgently needed. Lifileucel (LN-144) LN-145 centrally manufactured (cryopreserved drug-product, 22-day manufacturing process) autologous TIL products that have demonstrated activity in melanoma, cervical cancer, head neck carcinoma.<sup>1–4</sup>...
CCAAT/Enhancer Binding Proteins family proteins are important regulators of liver functions. Here, we show the critical role C/EBPα-mediated chromatin remodeling in age-associated dysfunctions and maintenance physiological homeostasis. Because ph-S193 isoform C/EBPα is increased livers old mice, have generated C/EBPα-S193D knockin which mimic C/EBPα. Analyses these mice showed that S193D mutation causes leading to histological appearance 'foci-like' nodules, also observed mice. These...
Highlights•Rogaratinib failed to improve PFS in patients with advanced squamous lung cell carcinomas overexpressing FGFR mRNA.AbstractBackgroundPatients squamous-cell cancer (SQCLC) frequently (46%) exhibit tumor overexpression of fibroblast growth factor receptor (FGFR) messenger ribonucleic acid (mRNA). Rogaratinib is a novel oral pan-FGFR inhibitor good safety profile and anti-tumor activity early clinical trials as single agent pathway-addicted tumors. SAKK 19/18 determined rogaratinib...
8547 Background: Neoadjuvant chemo-immunotherapy has become a new standard of care in locally advanced, resectable NSCLC. The SAKK 16/14 trial demonstrated major improvement pathological response (pCR), remission (MPR) and event-free survival (EFS) with the addition perioperative durvalumab after induction chemotherapy (ChT) cisplatin docetaxel. Based on data suggesting potential enhancement immunotherapy efficacy, ongoing 16/18 investigates immune-modulatory radiotherapy (RT) given...
TLD-1 is a novel pegylated liposomal doxorubicin (PLD) formulation aiming to optimise the PLD efficacy-toxicity ratio. We aimed characterise TLD-1's population pharmacokinetics using non-compartmental analysis and nonlinear mixed-effects modelling.
Abstract The BRAF kinase is attracting a lot of attention in oncology as alterations its amino acid sequence can constitutively activate the MAP signaling pathway, potentially contributing to malignant transformation cell but at same time rendering it sensitive targeted therapy. Several pathologic variants were grouped three different classes (I, II and III) based on their effects protein activity pathway. Discerning class mutation permits adapt treatment proposed patient. However, this...
Abstract Purpose. Lisavanbulin (BAL101553) is the prodrug of avanbulin (BAL27862), a microtubule-destabilizing agent. The goal this study (NCT02895360) was to characterize safety, tolerability and antitumor activity lisavanbulin administered as 48-hour intravenous (IV) infusion at recommended Phase 2 dose (RP2D) 70 mg/m . Results from 1 dose-escalation portion identifying RP2D have been previously reported. Here, we present findings 2a study. Methods. This multi-center, open-label included...
In patients with non-small cell lung cancer (NSCLC) harboring a fusion of the neurotrophic receptor kinase (NTRK) gene 1 or 3, treatment tropomyosin (TRK) inhibitors have shown promising results, however so far no data on efficacy these agents in NSCLC and NTRK2 are available. We present case female patient NTRK2-positive complete ongoing response therapy larotrectinib, suggesting first-generation TRK also NSCLC.